I would like to know the correlation and prevalence of HELLP / Preeclampsia and Polycystic Kidney Disease.
Women with polycystic kidney disease (PKD) are at higher risk of all forms of preeclampsia. It takes a lot of time to collect a group of women who have PKD that is large enough to conduct pregnancy studies. Very little research has been done, and most of the work on this question is done by looking back at records. One such study looked at the records of 343 women with this diagnosis, and compared their pregnancy outcomes with those of family members without PKD. That research - on women with pregnancies between 1985 and 1993 - found that women with PKD are more likely to develop high blood pressure during pregnancy, more likely to have severely high readings during pregnancy, and more likely to develop preeclampsia than their relatives.
Another observational study compared pregnant women with PKD to pregnant women with kidney cysts not caused by PKD, and found that preeclampsia, gestational hypertension, and chronic hypertension that got worse during pregnancy were all more likely to occur in the women with PKD. The dates on this ran from 1975 to 2010 and 54 women were in the PKD group. Because these populations are fairly small, it’s hard to say exactly what the rate of preeclampsia or HELLP would be. When 8 women out of a group of 92 develop preeclampsia, that might mean that doubling the size of the group to 184 would change the frequency with preeclampsia to 20 cases instead of 16 cases of preeclampsia, because of some other factors that did not affect the first, smaller, group. Right now scientists think that the rate of preeclampsia is somewhere around two to three times higher. So if 5% of the normal population develops preeclampsia while pregnant (that is 1 in 20 pregnancies), somewhere between 10-15% of the PKD population would (or around 2 to 3 of every 20 pregnancies.) Women with polycystic kidney disease might consult with a kidney specialist (a nephrologist) along with a maternal-fetal medicine specialist in order to determine the best possible course of care before becoming pregnant.
ASK AN EXPERT
This article is a response to research questions submitted by Preeclampsia Registry participants. If you have a research idea or question, enroll in the registry or login and select "Submit a Research Question" from your registry home page.
About Caryn Rogers
Senior Science Writer
Caryn Rogers is the Senior Science Writer at the Preeclampsia Foundation. As a community moderator, she has dedicated 15 years to creating clear, understandable explanations of the science underpinning preeclampsia so that women can use this knowledge to protect their own interests. Published in the Journal of Medicine and Philosophy and in Pregnancy Hypertension, Caryn uses her experience with philosophy of evolutionary medicine to support the Preeclampsia Foundation's mission. She developed preeclampsia with severe features at 33 weeks in 2002. After a week in the NICU, her son recovered well. Her daughter was born at 39 weeks after a normotensive pregnancy.
Your story is needed to improve outcomes for moms like you. Add your voice to critical preeclampsia research to ensure that every story is heard.
The Preeclampsia Foundation's published research results.
Frequently asked questions about the Preeclampsia Registry, a patient-driven registry and biobank.
The Preeclampsia Foundation offers research funding, study recruitment, and other patient engagement services to researchers.
We provide research grant funding to advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy.
May 19, 2023 – NEW YORK – Thermo Fisher Scientific announced on Friday, May 19 that it has obtained clearance from the US Food and Drug Administration for two assays to assess risk of...
A new research study published out of the UK in April 2023 in Hypertension found that more than half of all preeclampsia cases which occur during weeks 37-42 of pregnancy (“at-term”) may b...
Long-term neurodevelopmental follow-up of children exposed to pravastatin in utero If given in early pregnancy pravastatin, (a drug used to lower cholesterol) may decrease the risk of developing pree...
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy (a rat model) Currently the only treatment for preeclampsia starts with delivery of the baby and the placenta....
The nuMom2b study – short for “Nulliparous* Pregnancy Outcomes Study: Monitoring Mothers-To-Be” – is a prospective study that enrolled over 10,000 first time pregnant women acr...